Alnylam Provides Timing for New Pipeline Programs, Inks Two Deals for Biotherapeutics Initiative | GenomeWeb

By Doug Macron

Officials from Alnylam Pharmaceuticals last week presented additional details on the company's pipeline, which underwent a makeover of sorts last month with the unveiling of a new product-development strategy, and said that the firm remains on track to have five products in “advanced” clinical development by 2015.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.